Suppression of phase 2 ventricular fibrillation in acute myocardial infarction is a neglected but necessary target for antiarrhythmic drug development to prevent sudden cardiac death.
No takes yet. Share an insight, caveat, or question.
Current antiarrhythmic strategies may overlook phase 2 VF; leaves open whether dual suppression improves SCD protection in AMI.
Clements‐Jewery et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: